<http://schema.org/description>
"Results from three Phase III clinical trials (ION-1, ION-2 and ION-3) evaluating the investigational once-daily fixed-dose combination of the nucleotide analogue polymerase inhibitor sofosbuvir (SOF) 400mg and the NS5A inhibitor ledipasvir (LDV) 90mg, with and without ribavirin (RBV), for the treatment of genotype 1 chronic hepatitis C virus (HCV) infection have been presented at the International Liver Congress 2014."^^<http://www.w3.org/2001/XMLSchema#string>
<http://medicalxpress.com/news/2014-04-svr12-once-daily-combination-hcv-genotype.html>